VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.

Is now the time to buy VTRS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s performance to strong commercial execution in Greater China, where investments in established brands and e-commerce channels drove double-digit growth. CEO Scott Smith emphasized that demand for cardiovascular products and the company’s strategic focus on higher-margin generics in North America contributed meaningfully, while supply chain disruptions and lower-margin product headwinds in emerging markets weighed on results.

Looking ahead, management’s updated guidance is shaped by anticipated product launches and ongoing cost containment. The company expects recently approved products, such as the Gwyn Lo contraceptive patch and the potential launch of fast-acting meloxicam, to support growth. CFO Paul Campbell noted that near-term challenges, including manufacturing disruptions and policy changes in China, are factored into the outlook. Management highlighted ongoing investments in pipeline assets like selatogrel and cenerimod, which are expected to be key long-term growth drivers.

Key Insights from Management’s Remarks

Management identified strong commercial execution in China, new product momentum, and cost discipline as key drivers of the quarter, while also noting evolving challenges in supply and policy.

• China’s commercial momentum: Management highlighted double-digit growth in Greater China, driven by demand for cardiovascular products and increased e-commerce sales. CEO Scott Smith said, “We continue to see real and strong demand for the iconic brands that we have in China.”
• Product pipeline advancement: The company received FDA approval for Gwyn Lo, a once-weekly contraceptive patch, and is preparing for the U.S. launch of fast-acting meloxicam pending regulatory review. Chief R&D Officer Philippe Martin described Gwyn Lo’s approval as “reflect[ing] the strength of our clinical program.”
• Transdermal and generics strength: North America saw solid results from complex generics and transdermal products, including strong demand for estradiol patches following regulatory changes. Management noted supply constraints limited the ability to meet all demand.
• Cost discipline yielding leverage: Management credited the enterprise-wide strategic review and cost containment for enhanced operating leverage, which supported non-GAAP profitability even as GAAP margins compressed.
• Portfolio reshaping: The company agreed to divest global rights to Tyrvaya, signaling a shift away from eye care to prioritize higher-growth opportunities. Management also completed the sale of its Biocon equity stake, providing additional financial flexibility.

Drivers of Future Performance

Viatris’ updated outlook is driven by the launch of new branded products, ongoing pipeline execution, and cost discipline, but is tempered by supply and policy uncertainties.

• Upcoming product launches: Management expects recently approved and soon-to-launch products, such as Gwyn Lo and fast-acting meloxicam, to be significant contributors to revenue and margin expansion. Commercial plans target non-opioid pain management needs and increased adoption of transdermal therapies.
• China policy and supply risks: The company anticipates policy changes in China’s hospital procurement and intermittent manufacturing disruptions at its Nashik facility will moderate growth, particularly for lower-margin products. CEO Scott Smith noted execution of remediation plans, but expects near-term impact on specific product lines.
• Pipeline and business development execution: Pipeline assets like selatogrel and cenerimod remain on track for major clinical milestones in 2027. Management is actively pursuing business development opportunities, with CFO Paul Campbell emphasizing a disciplined approach to M&A amid an active deal environment.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will be closely monitoring (1) the commercial launch and uptake of fast-acting meloxicam and Gwyn Lo, (2) the resolution of manufacturing disruptions at the Nashik facility and associated supply chain impacts, and (3) the evolving policy environment in China and its effect on hospital channel sales. Progress on pipeline milestones and clarity on business development initiatives will also be key signposts for execution.

Viatris currently trades at $16.82, down from $17.65 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.